327046-79-7

Basic information

• Product Name: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester;N-(4-BroMo-2-nitrophenyl)carbaMic Acid tert-Butyl Ester;tert-butyl (4-bromo-2-nitrophenyl)carbamate;(4-Bromo-2-nitro-phenyl)-carbamic acid tert-butyl ester
• CAS NO: 327046-79-7
• Molecular Formula: C₁₁H₁₃BrN₂O₄
• Molecular Weight: 317.13592
• Product Categories: Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 327046-79-7.mol

Chemical Properties

• Boiling Point: 337.8±32.0 °C(Predicted)
• Appearance: /
• Density: 1.535±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: Chloroform, Dichloromethane, Methanol
• PKA: 11.70±0.70(Predicted)
• CAS DataBase Reference: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(327046-79-7)
• EPA Substance Registry System: CarbaMic acid, N-(4-broMo-2-nitrophenyl)-, 1,1-diMethylethyl ester(327046-79-7)

Safety Data

• Hazardous Substances Data: 327046-79-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CarbaMic acid, N-(4-bromo-2-nitrophenyl)-, 1,1-dimethylethyl ester is used as a reactant for the optimization of selective HDAC1/HDAC2 inhibitors. It aids in the development of drugs that can specifically target these HDAC isoforms, which are involved in the regulation of gene expression and have been implicated in various diseases, including cancer, neurological disorders, and cardiovascular diseases.
Used in Drug Synthesis:
CarbaMic acid, N-(4-bromo-2-nitrophenyl)-, 1,1-dimethylethyl ester is used in the preparation of selective HDAC inhibitors. These inhibitors have potential therapeutic applications in the treatment of various diseases by modulating the activity of specific HDAC isoforms, leading to changes in gene expression and cellular function. The development of selective HDAC inhibitors can help improve the efficacy and safety of treatments for these conditions.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 875-51-4 4-Bromo-2-nitroaniline 
• 88-74-4 2-nitro-aniline 
• 131818-17-2 tert-butyl (4-bromophenyl)carbamate 
• 1228392-59-3 N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester 

Downstream Products

• 855738-60-2 tert-butyl 2-nitro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate 
• 335254-95-0 tert-butyl (2-nitro-4-(thiophen-2-yl) phenyl)carbamate 
• 954239-15-7 tert-butyl (2-amino-4-bromophenyl)carbamate 
• 1306598-86-6 6-(4-fluorophenyl)-3-(imidazo[1,2-a]pyridin-3-yl)-2-methylquinoxaline 
• 1306598-88-8 7-(4-fluorophenyl)-2-(2-methylimidazo[1,2-b]pyridazin-3-yl)quinoxaline 
• 1228793-70-1 BRD-9460 
• 1228793-82-5 BRD-0063 
• 1228793-78-9 BRD-4029 
• 1426328-40-6 4-(3-cyanophenyl)-2-oxo-2,3-dihydro-1H-benzo[b][1,4]diazepine-8-carboxylic acid 
• 1426328-41-7 2-(4-(3-cyanophenyl)-2-oxo-2,3-dihydro-1H-benzo[b][1,4]diazepin-8-yl)benzoic acid 
• 1426328-42-8 methyl 4-(3-cyanophenyl)-2-oxo-2,3-dihydro-1H-benzo[b][1,4]diazepine-8-carboxylate 
• 1426328-44-0 4-(3-cyanophenyl)-2-oxo-N-propyl-2,3-dihydro-1H-benzo[b][1,4]diazepine-8-carboxamide 
• 1426328-47-3 4-(3-cyanophenyl)-N-methyl-2-oxo-2,3-dihydro-1H-benzo[b][1,4]diazepine-8-carboxamide 
• 1430236-50-2 methyl 3-(4-(3-cyanophenyl)-2-oxo-2,3-dihydro-1H-benzo[b][1,4]diazepin-8-yl)benzoate 

Relevant articles and documents

Ring size changes in the development of class I HDAC inhibitors

Five pathways involving different ring structures led to generation of fourteen thienylbenzamides (7–20) which display the structure-activity relationships of class I HDAC inhibitors. All the synthesised compounds inhibit HDAC1 and HDAC2 selectively over other isoforms and many inhibit DLD1 and HCT116 cells more effectively than a parent compound. Compounds 8 and 16 inhibit HCT116 cells by activation of the apoptosis pathway.

Design and Synthesis of Novel N-(2-aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study

Histone deacetylases (HDACs) are promising therapeutic targets for cancer therapy because inhibition of HDACs triggers growth arrest or apoptosis of tumor cells. In the present study, a new series of fluorinated N-(2-aminophenyl)benzamide derivatives were synthesized to investigate potential inhibition of HDACs and associated anticancer activity. Among the synthesized derivatives, compound 24a showed potent inhibitory activity of HDACs and higher antitumor efficacy in human cancer cell lines (HCT-116, MCF-7, and A549) compared with SAHA. Moreover, animal studies demonstrated that compound 24a showed potent in vivo antitumor efficacy in an HCT-116 colon cancer xenograft mouse model.

HDAC DEGRADER

The disclosure provides compounds of formula (I). The compounds may be used to degrade the Histone Deacetylase (HDAC) family of enzymes, particularly HDAC1, 2 and 3 that exist in corepressor complexes. Accordingly, the compounds may

PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally substituted by one ormore substituents selected from alkyl, cycloalkyl, halo, alkoxy, CN, haloalkyl and OH; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, C land alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl,Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl andhaloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl,SO2NR12R13, heteroaryl, CONR10R11 and alkyl, wherein said heteroaryl group is optionallysubstituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R8 is selected from H, alkyl, haloalkyl and halo; and R9 is H, alkyl or halo; R10 and R11 are each independently H or alkyl; and R12 and R13 are each independently H or alkyl. Further aspects of the invention relate to such compounds for use in the field of immuno- oncology and related applications. Another aspect of the invention relates to compounds of formulae (la) and (lb).

URSODEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF POLYCYSTIC DISEASES

The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autos

PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE

The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.

Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof

The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurode

HETEROCYCLICS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

This disclosure relates to heterocyclics as selective inhibitors of the fibroblast growth factor receptor 4 (FGFR-4), in particular relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound.

Visible-Light-Mediated Nitration of Protected Anilines

The photocatalytic nitration of protected anilines proceeds with riboflavin tetraacetate as an organic photoredox catalyst. Sodium nitrite serves as the NO2 source in this visible-light-driven room temperature reaction. Various nitroanilines are obtained in moderate to good yields without the addition of acid or stoichiometric oxidation agents. The catalytic cycle is closed by aerial oxygen as the terminal oxidant.

HETEROBICYCLIC N-AMINOPHENYL-AMIDES AS INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.